🎗️ Melanoma — 2026-W40

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Translational multi-omics analysis in JCO integrating data from several randomized melanoma trials (IMspire150, BRIM, AVAST-M) to define transcriptional tumor states predicting response to immune checkpoint blockade versus BRAF/MEK inhibitor plus ICB combinations. Suggests a biomarker framework for selecting therapy sequencing in BRAF-mutant melanoma, with validation across clinical cohorts.